CDH1 and neoplasm: Finally, in the melanoma cohort, the presence of <49% Ecad+ cancer cells, and more than 22% Vim+ cancer cells, 16% CD80+ cancer cells, 18% CD155+ cancer cells, and 9% Ecad−Vim+, Ecad−CD80+ and Ecad−CD155+ cancer cells might be risk factors for tumor relapse after adjuvant anti-PD-1 therapy (Supplementary Figs. 8k–o and 9i–l).